“BMI and TLC Influences Doxorubicin/Epirubicin Neoadjuvant Chemotherapy Response in Patients with Locally Advanced Breast Cancer”, MKB, vol. 54, no. 4, pp. 221–227, Dec. 2022, doi: 10.15395/mkb.v54n4.2797.